Mylan Pharmaceuticals Seeks DEA Approval to Import Remifentanil
February 15, 2025
February 15, 2025
WASHINGTON, Feb. 15 (TNSFR) -- The Drug Enforcement Administration has announced that Mylan Pharmaceuticals, Inc. has applied for registration to import Remifentanil, a Schedule II controlled substance, at its facility in Greensboro, North Carolina.
The company intends to bring in the drug in finished dosage form for commercial distribution to its customers. Remifentanil, an ultra-short-acting synthetic opioid used primarily for anesthesia and pain management, is subject to strict . . .
The company intends to bring in the drug in finished dosage form for commercial distribution to its customers. Remifentanil, an ultra-short-acting synthetic opioid used primarily for anesthesia and pain management, is subject to strict . . .